Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

ELAB

P

PMGC Holdings Inc. (ELAB)

NCM – Цена в реальном времени. Валюта: USD

1.67

-0.20 (-10.70%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

3.34

+1.67 (100.00%)

После закрытия: Mar 27, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

SVM Machining, Inc. Secures ITAR Registration, Enabling Entry into U.S. Defense Manufacturing Contracts

SVM Machining, Inc. Secures ITAR Registration, Enabling Entry into U.S. Defense Manufacturing Contracts

NEWPORT BEACH, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: PMGC) (“PMGC” or the “Company”), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, is pleased to announce that its wholly owned subsidiary, SVM Machining, Inc. dba Silicon Valley Manufacturing (“SVM”), has completed International Traffic in Arms Regulations (“ITAR”) registration and is in compliance with ITAR.

NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

NEWPORT BEACH, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive Biosciences Inc. (“NorthStrive Biosciences”).

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

NEWPORT BEACH, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-6 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on March 10, 2026.

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals

NEWPORT BEACH, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences, Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced the filing of ten (10) new U.S. patent applications expanding its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, including applications designed to encourage animals to grow new muscle and increase muscle weight return per animal.

NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health

NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health

NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservati

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

NEWPORT BEACH, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (“PMGC”), today announced a progress update to the anticipated completion timeline for Phase III of its AI Development Program with strategic partner Yuva Biosciences, Inc. (“Yuva Biosciences”).

PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.

PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.

NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”), a diversified public holding company announced that it has completed the acquisition of SVM Machining, Inc. (“SVM”).

Видео

No Data

There is no data to display

Пресс-релизы

SVM Machining, Inc. Secures ITAR Registration, Enabling Entry into U.S. Defense Manufacturing Contracts

SVM Machining, Inc. Secures ITAR Registration, Enabling Entry into U.S. Defense Manufacturing Contracts

NEWPORT BEACH, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: PMGC) (“PMGC” or the “Company”), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, is pleased to announce that its wholly owned subsidiary, SVM Machining, Inc. dba Silicon Valley Manufacturing (“SVM”), has completed International Traffic in Arms Regulations (“ITAR”) registration and is in compliance with ITAR.

NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

NEWPORT BEACH, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive Biosciences Inc. (“NorthStrive Biosciences”).

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

NEWPORT BEACH, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-6 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on March 10, 2026.

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals

NEWPORT BEACH, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences, Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced the filing of ten (10) new U.S. patent applications expanding its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, including applications designed to encourage animals to grow new muscle and increase muscle weight return per animal.